If you deal with recurrent UTIs, a new FDA-approved antibiotic called Blujepa could offer another treatment option—especially as antibiotic resistance grows. While it’s currently approved for females ...

A new antibiotic to treat stubborn urinary tract infection (UTI) and a blood-clot-dissolving intravenous treatment for acute ...

The Food and Drug Administration has approved a new antibiotic that can treat uncomplicated urinary tract infections, or ...

This antibiotic is the first new FDA-approved medication for urinary tract infections in decades, and meets the need for new ...

The US Food and Drug Administration (FDA) has early this week approved GSK's new antibiotic, Blujepa (gepotidacin), for the treatment of uncomplicated urinary tract infections (UTIs) in women aged 12 ...

The medication, gepotidacin, targets E. coli bacteria, which is responsible for the most common types of infections, called uncomplicated UTIs, that affect women. Advertisement Advertisement Called ...

GSK's pill, the first oral antibiotic for urinary tract infections in almost 30 years, comes as bacteria are increasingly ...

A GSK pill that offers a lower potential for drug resistance is now FDA approved as a new treatment for a common type of urinary tract infection, the first new oral antibiotic for this indication ...

London: GSK plc has announced that the Company has received US Food and Drug Administration (FDA) approval for Blujepa (gepotidacin) for the treatment of female adults (≥40 kg) and paediatric patients ...

The FDA has approved GSK's gepotidacin (Blujepa) for treating uncomplicated urinary tract infections (uUTIs) in females aged 12 and older. The approval is based on successful phase 3 EAGLE-2 and EAGLE ...